SCHEMBL14744897

SCHEMBL14744897

CCC/C(=N\Cc1ccc(OC)cc1OC)c1ccc2c(c1)cc(C1CCN(C(=O)OC(C)(C)C)C1)n2C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.42
PDE4A P27815 2/20 0.42
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42
MAPT P10636 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
STS P08842 1/20 0.38
EPHX2 P34913 1/20 0.38
CNR2 P34972 1/20 0.36
HTT P42858 1/20 0.36
KDM2B Q8NHM5 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
TP53 P04637 1/20 0.35
LMNA P02545 1/20 0.35
TNKS O95271 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14741318 1.00 PDE4B (0.42) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL14745515 0.81 PDE4A (0.39) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL14745227 0.80 PDE4D (0.53) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL14745044 0.75 KMT2A (0.41) PDE4BMAPTMEN1KMT2ASTS
SCHEMBL14745921 0.74 LMNA (0.37) MAPTMEN1KMT2ATP53LMNA
SCHEMBL14745920 0.74 LMNA (0.37) MAPTMEN1KMT2ATP53LMNA
SCHEMBL14745171 0.73 MAPT (0.37) PDE4BMAPTMEN1KMT2ASTS
SCHEMBL16428739 0.72 NPC1 (0.33) MAPTMEN1KMT2ATP53LMNA
SCHEMBL14741305 0.71 MAPT (0.32) MAPTMEN1KMT2ATP53LMNA
SCHEMBL14744932 0.70 USP30 (0.56) PDE4BMAPTGPR119KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP PDE4B 3185/4885PDE4A 3118/4885PDE4C 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.